Clinical Implications of Serum LDH，CysC，and PWR Level Detection in Lung Cancer Patients
-
摘要:
目的 探究肺癌患者血清乳酸脱氢酶（LDH）、半胱氨酸蛋白酶抑制剂C（CysC）、血小板/白细胞比值（PWR）水平检测意义。 方法 2023年1月至2023年6月选取常州市第四人民医院72例肺癌患者设为观察组，另选取同期肺部良性病变患者72例设为对照组，比较2组LDH、CysC、PWR及各项肿瘤标志物[癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）、细胞角蛋白片段19（CYFRA21-1）]，分析LDH、PWR、CysC与各项肿瘤标志物的相关性；比较不同病理特征肺癌患者LDH、CysC、PWR水平，分析肺癌患者LDH、PWR、CysC水平与病理特征的相关性，评价LDH、CysC、PWR结合CEA、CYFRA21-1、NSE对肺癌的诊断价值。 结果 观察组PWR低于对照组，LDH、CysC、CEA、CYFRA21-1及NSE高于对照组（P < 0.05）。肺癌患者PWR与肿瘤标志物CEA、CYFRA21-1、NSE呈负相关（ P < 0.05），LDH、CysC与肿瘤标志物CEA、CYFRA21-1、NSE呈正相关（ P < 0.05）。病理类型方面：肺腺癌与肺鳞癌患者LDH、CysC、PWR比较，差异无统计学意义（ P > 0.05）；临床分期方面：Ⅰ～Ⅱ期患者PWR高于Ⅲ～Ⅳ期患者，LDH、CysC低于Ⅲ～Ⅳ期患者（ P < 0.05）；有无淋巴结转移方面：无淋巴结转移患者PWR高于有淋巴结转移患者，LDH、CysC低于有淋巴结转移患者（ P < 0.05）。肺癌患者LDH、PWR、CysC与病理类型无关（ P > 0.05），PWR与临床分期、淋巴结转移呈负相关（ P < 0.05），LDH、CysC与临床分期、淋巴结转移呈正相关（ P < 0.05）。（ROC）曲线显示，LDH、CysC、PWR联合诊断肺癌的曲线下面积（AUC）值为0.910，CEA、CYFRA21-1及NSE联合诊断AUC值为0.923，进一步采用LDH、CysC、PWR结合CEA、CYFRA21-1、NSE诊断AUC值最高，为0.940，敏感度、特异度分别为93.06%、87.33%。 结论 肺癌患者PWR下降，LDH、CysC水平升高，且其水平与肿瘤标志物、临床分期及淋巴结转移密切相关，可辅助肿瘤标志物对肺癌进行诊断，以期提高早期肺癌诊断率。 -
关键词:
- 肺癌 /
- 乳酸脱氢酶 /
- 半胱氨酸蛋白酶抑制剂C /
- 血小板/白细胞比值
Abstract:Objective To investigate the clinical implications of lung function index, serum lactate dehydrogenase（LDH）, cysteine protease inhibitor C（CysC） and platelet/white blood cell ratio（PWR） in patients with lung cancer. Methods From January 2023 to June 2023, 72 patients with lung cancer in the Fourth People's Hospital of Changzhou were selected as the observation group, and 72 patients with benign lung diseases during the same period were selected as the control group. LDH, CysC, PWR and tumor markers [carcinoembryonic antigen（CEA）, neuron-specific enolase（NSE）, cytokeratin fragment 19（CYFRA21-1）] were compared between the two groups, and the correlation between LDH, PWR, CysC and tumor markers was analyzed. The levels of LDH, CysC and PWR in patients with lung cancer with different pathological characteristics were compared, and the correlation between the levels of LDH, PWR, CysC and pathological characteristics in patients with lung cancer was analyzed. The diagnostic value of LDH, CysC, PWR combined with CEA, CYFRA21-1 and NSE in lung cancer was evaluated. Results The PWR of the observation group was lower than that of the control group, and the LDH, CysC, CEA, CYFRA21-1 and NSE were higher than those of the control group（P < 0.05）. PWR was negatively correlated with tumor markers CEA, CYFRA21-1 and NSE（ P < 0.05）, LDH and CysC were positively correlated with tumor markers CEA, CYFRA21-1 and NSE（ P < 0.05）. There was no significant difference in LDH, CysC and PWR between lung adenocarcinoma and lung squamous cell carcinoma（ P > 0.05）. In terms of clinical stage, PWR of stage Ⅰ- Ⅱ patients was higher than that of stage Ⅲ-Ⅳ patients, LDH and CysC were lower than those of stage Ⅲ-Ⅳ patients（ P < 0.05）. In terms of lymph node metastasis, the PWR of patients without lymph node metastasis was higher than that of patients with lymph node metastasis, and LDH and CysC were lower than those of patients with lymph node metastasis（ P < 0.05）. LDH, PWR and CysC in lung cancer patients were not correlated with pathological type（ P > 0.05）, PWR was negatively correlated with clinical stage and lymph node metastasis（ P < 0.05）, LDH and CysC were positively correlated with clinical stage and lymph node metastasis（ P < 0.05）. The ROC curve showed that the area under the curve（AUC） value of the combination of LDH, CysC and PWR in the diagnosis of lung cancer was 0.910, and the AUC value of the combination of CEA, CYFRA21-1 and NSE was 0.923. Further use of LDH, CysC, PWR combined with CEA, CYFRA21-1, NSE diagnostic AUC value was the highest, 0.940, the sensitivity and specificity were 93.06% and 87.33%, respectively. Conclusion The PWR of lung cancer patients is decreased, and the levels of LDH and CysC are increased, and their levels are closely related to tumor markers, clinical stage and lymph node metastasis, which can assist tumor markers in the diagnosis of lung cancer, in order to improve the diagnosis rate of early lung cancer. -
图 1 LDH、CysC、PWR及肿瘤标志物诊断肺癌的ROC曲线
A：LDH、CysC、PWR诊断；B：肿瘤标志物诊断；C：联合诊断。
Figure 1. ROC curve of lung function index，LDH，CysC，PWR and tumor markers in the diagnosis of lung cancer
表 1 2组一般资料比较[n/（ $\bar x \pm s $）]
Table 1. Comparison of general information of the two groups[n/（ $\bar x \pm s $）]
组别 n 性别（男/女） 年龄（岁） 体质量指数（kg/m2） 观察组 72 47/25 58.76±7.27 21.59±1.24 对照组 72 43/29 57.83±8.46 21.34±1.17 t/χ2 0.474 0.707 1.224 P 0.491 0.480 0.215 
下载: 导出CSV
表 2 2组LDH、CysC、PWR比较（ $ \bar x \pm s $）
Table 2. Comparison of LDH，CysC，PWR between two groups （ $ \bar x \pm s$）
组别 n LDH（U/L） CysC（mg/L） PWR 观察组 72 180.72±44.16 0.86±0.09 32.60±8.43 对照组 72 95.37±23.25 0.65±0.07 37.41±5.06 t 14.511 15.628 4.151 P <0.001* <0.001* <0.001* *P<0.05。
下载: 导出CSV
表 3 2组各项肿瘤标志物比较（ $ \bar x \pm s $）
Table 3. Comparison of various tumor markers between two groups （ $ \bar x \pm s $）
组别 n CEA（ng/mL） CYFRA21-1（ng/mL） NSE（ng/mL） 观察组 72 4.17±1.24 5.04±1.45 15.43±3.58 对照组 72 2.18±0.85 2.46±0.94 8.52±2.77 t 11.232 12.669 12.953 P <0.001* <0.001* <0.001* *P<0.05。
下载: 导出CSV
表 4 LDH、CysC、PWR与各项肿瘤标志物的相关性分析
Table 4. Correlation analysis of LDH，CysC，PWR with various tumor markers
指标 CEA CYFRA21-1 NSE LDH r 0.602 0.637 0.620 P <0.001* <0.001* <0.001* CysC r 0.614 0.625 0.618 P <0.001* <0.001* <0.001* PWR r −0.507 −0.501 −0.517 P <0.001* <0.001* <0.001* *P<0.05。
下载: 导出CSV
表 5 不同病理特征患者LDH、CysC、PWR水平比较（ $\bar x \pm s $）
Table 5. Comparison of LDH，CysC，and PWR levels in patients with different pathologic features （ $ \bar x \pm s$）
病理特征 n LDH（U/L） CysC（mg/L） PWR 病理类型 肺腺癌 55 180.49±45.27 0.86±0.07 32.74±8.14 肺鳞癌 17 181.46±40.13 0.86±0.10 32.15±7.98 t 0.079 0.000 0.262 P 0.937 1.000 0.794 临床分期 Ⅰ～Ⅱ期 48 175.41±25.16 0.82±0.08 34.88±9.25 Ⅲ～Ⅳ期 24 191.34±28.37 0.94±0.14 28.04±6.07 t 2.214 4.456 2.857 P 0.030* <0.001* 0.006* 淋巴结转移 有 19 209.47±50.12 1.05±0.12 26.19±6.98 无 53 170.41±32.06 0.79±0.08 34.90±9.12 t 3.020 8.356 4.172 P 0.004* <0.001* 0.025* *P<0.05。
下载: 导出CSV
表 6 肺癌患者LDH、CysC、PWR水平与病理特征的相关性
Table 6. Correlation of LDH，CysC，and PWR levels with pathologic features in lung cancer patients
指标 病理类型 临床分期 淋巴结转移 LDH r 0.114 0.604 0.611 P 1.569 <0.001* <0.001* CysC r 0.129 0.598 0.634 P 1.710 <0.001* <0.001* PWR r 0.094 -0.579 -0.621 P 1.409 <0.001* <0.001* *P<0.05。
下载: 导出CSV
表 7 LDH、CysC、PWR结合肿瘤标志物对肺癌的诊断价值
Table 7. Diagnostic value of LDH，CysC，and PWR combined with tumor markers in lung cancer
指标 AUC（95%CI） Z统计 截断值 敏感度（%） 特异度（%） P LDH（U/L） 0.842（0.772～0.897） 10.141 180.81 65.28 83.06 <0.001* CysC（mg/L） 0.772（0.695～0.838） 6.991 0.82 65.28 77.78 <0.001* PWR 0.727（0.647～0.798） 5.331 40.24 83.33 55.56 <0.001* 3项联合诊断
0.917（0.860～0.957） 16.759 / 83.92 89.28 <0.001* CEA（ng/mL） 0.751（0.672～0.819） 6.165 4.03 62.50 83.33 <0.001* CYFRA21-1（ng/mL） 0.742（0.662～0.811） 5.792 4.35 66.67 77.78 <0.001* NSE（ng/mL） 0.821（0.749～0.880） 9.030 15.00 68.06 87.50 <0.001* 3项联合诊断 0.923（0.867～0.961） 17.951 / 84.72 90.28 <0.001* 6项联合诊断 0.940（0.888～0.973） 24.267 / 93.06 87.33 <0.001* *P<0.05。
下载: 导出CSV
-
[1] Thai A A,Solomon B J,Sequist L V,et al. Lung cancer[J]. Lancet,2021,398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3 [2] Nooreldeen R,Bach H. Current and future development in lung cancer diagnosis[J]. Int J Mol Sci,2021,22(16):8661. doi: 10.3390/ijms22168661 [3] Oliver A L. Lung cancer: Epidemiology and screening[J]. Surg Clin North Am,2022,102(3):335-344. doi: 10.1016/j.suc.2021.12.001 [4] 夏进,陈培,官和立,等. 早期肺癌筛查人群患病风险队列研究[J]. 现代预防医学,2023,50(12):2284-2288. [5] 胡明明,阳苑,张同梅,等. 7843例原发肺恶性肿瘤流行病学特征分析[J]. 现代肿瘤医学,2021,29(4):682-685. doi: 10.3969/j.issn.1672-4992.2021.04.031 [6] Liam C K,Lee P,Yu CJ,et al. The diagnosis of lung cancer in the era of interventional pulmonology[J]. Int J Tuberc Lung Dis,2021,25(1):6-15. doi: 10.5588/ijtld.20.0588 [7] 支修益,石远凯,于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志,2015,37(1):67-78. doi: 10.3760/cma.j.issn.0253-3766.2015.01.014 [8] 王敏,王媛,孙静,等. 人参养荣汤对Lewis肺癌糖酵解途径相关酶LDH-A、HK2基因表达的影响[J]. 辽宁中医杂志,2022,49(1):180-184. [9] 刘浩,刘文,向辉,等. 半胱氨酸蛋白酶抑制剂C对胃癌侵袭与转移的影响[J]. 吉林医学,2022,43(12):3194-3197. doi: 10.3969/j.issn.1004-0412.2022.12.007 [10] 李白坤,朱继民,李庆林. 血小板与白细胞相互作用介导的肿瘤炎症微环境及其中医药治疗策略[J]. 安徽中医药大学学报,2021,40(1):93-96. doi: 10.3969/j.issn.2095-7246.2021.01.023 [11] An J,Gu Q H,Cao L M,et al. Serum IL-6 as a vital predictor of severe lung cancer[J]. Ann Palliat Med,2021,10(1):202-209. doi: 10.21037/apm-20-2229 [12] Yu J Q,Du F,Yang LP,et al. Identification of potential serum biomarkers for simultaneously classifying lung adenocarcinoma,squamous cell carcinoma and small cell carcinoma[J]. Cancer Biomark,2021,30(3):331-342. doi: 10.3233/CBM-201440 [13] Xu C H,Li L,Wang W,et al. Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer[J]. J Cell Mol Med,2021,25(6):3169-3172. doi: 10.1111/jcmm.16360 [14] Kerr K M,Bibeau F,Thunnissen E,et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe[J]. Lung Cancer,2021,154(11):161-175. [15] 齐艳春,陈玲玲,全勍,等. ProGRP、CEA、NSE、CYFRA21-1、CA125、SCC对不同病理类型肺癌的诊断价值及联合检测的临床意义[J]. 牡丹江医学院学报,2023,44(3):62-66. [16] 王妮娜,李晓花,陈敏丽,等. 肺癌患者血清NSE,SCC,CA125及CYFRA21-1水平检测在不同病理类型早期诊断和化疗疗效评价中的应用价值[J]. 现代检验医学杂志,2021,36(1):33-37. doi: 10.3969/j.issn.1671-7414.2021.01.009 [17] 陈礼昌,滕凤猛. 血清肿瘤标志物在肺癌不同病理分型中的应用价值[J]. 临床误诊误治,2022,35(1):29-32,47. doi: 10.3969/j.issn.1002-3429.2022.01.008 [18] Qiu X,Shi Z,Tong F,et al. Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer[J]. Hum Vaccin Immunother,2023,19(1):2178791. doi: 10.1080/21645515.2023.2178791 [19] Lahoud R M,O'Shea A,El-Mouhayyar C,et al. Tumour markers and their utility in imaging of abdominal and pelvic malignancies[J]. Clin Radiol,2021,76(2):99-107. doi: 10.1016/j.crad.2020.07.033 [20] 王云,牛华,方浩徽. C反应蛋白/清蛋白比率乳酸脱氢酶预测非小细胞肺癌患者预后的应用价值[J]. 安徽医学,2022,43(8):912-917. doi: 10.3969/j.issn.1000-0399.2022.08.009 [21] 李冰. 恶性肿瘤血清同型半胱氨酸和胱抑素C检测的临床价值探讨[J]. 中国疗养医学,2015,24(11):1188-1189. [22] Winther-Larsen A,Aggerholm-Pedersen N,Sandfeld-Paulsen B. Inflammation scores as prognostic biomarkers in small cell lung cancer: A systematic review and meta-analysis[J]. Syst Rev,2021,10(1):40. doi: 10.1186/s13643-021-01585-w [23] 高心怡,陈丽,甘建和. MELD评分联合血小板/白细胞比值对HBV相关慢加急性肝衰竭患者预后的预测价值[J]. 临床肝胆病杂志,2021,37(5):1070-1074. doi: 10.3969/j.issn.1001-5256.2021.05.019 -
点击查看大图
图(1) / 表(7)
计量
- 文章访问数: 735
- HTML全文浏览量: 426
- PDF下载量: 9
- 被引次数: 0
